Evogene Ltd. ( (EVGN) ) has released its Q1 earnings. Here is a breakdown of the information Evogene Ltd. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Evogene Ltd., a computational biology company, leverages big data and artificial intelligence to develop life-science-based products, focusing on microbes, small molecules, and genetic elements through its tech-engines and subsidiaries.
In the first quarter of 2025, Evogene reported a decrease in total revenues to $2.4 million from $4.2 million in the same period last year, primarily due to the absence of significant license fee payments that were present in 2024. The company has implemented an expense reduction plan, which has begun to reflect in the financial results.
Key financial metrics highlight a reduction in R&D expenses to $3.2 million and sales and marketing expenses to $0.6 million, contributing to a decrease in the net loss to $3.0 million from $3.8 million in the previous year. The acquisition of Lavie Bio’s activities by ICL for $15.25 million, along with the sale of MicroBoost AI for Ag, is expected to generate value for Evogene.
Evogene’s strategic focus remains on advancing its ChemPass-AI tech-engine in the pharmaceutical sector and generating value from its subsidiaries. The company aims to unlock shareholder value through strategic partnerships and collaborations.
Looking ahead, Evogene’s management is optimistic about driving sustainable growth and achieving long-term success in the evolving life sciences landscape through its strategic initiatives and technological advancements.